{
    "pmcid": "8097376",
    "qa_pairs": {
        "How many unique nanobodies were identified from the alpaca immunized with the glycosylated SARS-CoV-2 RBD?": [
            "11",
            "8",
            "15",
            "5"
        ],
        "What is the name of the biparatopic nanobody developed by fusing NM1226 and NM1230?": [
            "NM1267",
            "NM1250",
            "NM1275",
            "NM1248"
        ],
        "What is the primary function of the SARS-CoV-2 spike protein's receptor-binding domain (RBD)?": [
            "Binding to the angiotensin-converting enzyme 2 (ACE2) on human epithelial cells",
            "Facilitating viral replication within host cells",
            "Triggering the host immune response",
            "Providing structural stability to the virus"
        ],
        "What technique was used for detailed epitope mapping of the nanobodies on the RBD?": [
            "Hydrogen-Deuterium Exchange Mass Spectrometry (HDX-MS)",
            "X-ray Crystallography",
            "Cryo-Electron Microscopy",
            "Nuclear Magnetic Resonance (NMR) Spectroscopy"
        ],
        "Which nanobodies were identified as the most potent inhibitors of the RBD:ACE2 interaction?": [
            "NM1228, NM1226, and NM1230",
            "NM1224, NM1225, and NM1227",
            "NM1231, NM1232, and NM1233",
            "NM1229, NM1234, and NM1235"
        ]
    }
}